The selective JAK1 inhibitor itacitinib was able to effectively reduce CRS-related cytokines produced by anti-CD19 CAR T cells in a dose-dependent fashion in both in vitro and in vivo models without impacting CAR T proliferation or cytolytic function. The gene discussed is CD19; the disease is congenital rubella syndrome.